These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21254913)

  • 21. Subjective interpretation of inconclusive BRCA1/2 cancer genetic test results and transmission of information to the relatives.
    Cypowyj C; Eisinger F; Huiart L; Sobol H; Morin M; Julian-Reynier C
    Psychooncology; 2009 Feb; 18(2):209-15. PubMed ID: 19061202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: review of the literature].
    Leblond D; Brédart A; Dolbeault S; De Pauw A; Stoppa Lyonnet D; Flahault C; Sultan S
    Bull Cancer; 2011 Feb; 98(2):184-98. PubMed ID: 21382771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychosocial aspects of genetic counseling and testing.
    Vadaparampil ST; Wey JP; Kinney AY
    Semin Oncol Nurs; 2004 Aug; 20(3):186-95. PubMed ID: 15491028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information.
    Himes DO; Clayton MF; Donaldson GW; Ellington L; Buys SS; Kinney AY
    J Genet Couns; 2016 Apr; 25(2):258-69. PubMed ID: 26245632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moving In and Out of the What-Ifs: The Experiences of Unaffected Women Living in Families Where a Breast Cancer 1 or 2 Genetic Mutation Was Not Found.
    Schroeder D; Duggleby W; Cameron BL
    Cancer Nurs; 2017; 40(5):386-393. PubMed ID: 27749355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
    Vos J; Gómez-García E; Oosterwijk JC; Menko FH; Stoel RD; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
    Psychooncology; 2012 Jan; 21(1):29-42. PubMed ID: 21072753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis.
    Keenan LA; Lesniak KT; Guarnaccia CA; Althaus B; Ethington G; Blum JL
    J Genet Couns; 2004 Apr; 13(2):157-76. PubMed ID: 15604630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and professionals' perspectives.
    Arts-de Jong M; Harmsen MG; Hoogerbrugge N; Massuger LF; Hermens RP; de Hullu JA
    Gynecol Oncol; 2015 Feb; 136(2):305-10. PubMed ID: 25560807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations.
    Kelly KM; Senter L; Leventhal H; Ozakinci G; Porter K
    Patient Educ Couns; 2008 Jan; 70(1):135-42. PubMed ID: 17988821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary Breast and ovarian cancer: providing personalized medicine.
    Tranin AS
    AWHONN Lifelines; 2005; 9(5):372-6. PubMed ID: 16359075
    [No Abstract]   [Full Text] [Related]  

  • 37. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 40. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.